Introduction
The human genome comprises of about 20% protein coding genes and 80% of non-coding genes [1] . The noncoding genes, once considered dark matter, currently show their capacity in protein regulation through direct transcriptional, indirect co-transcriptional and epigenetic mechanisms. The non-coding RNAs consist of a huge and diverse class of members that include rRNAs, tRNAs, small nuclear RNAs, endogenous siRNAs, PIWIinteracting RNAs, long non coding RNAs and microRNA (miRNAs). miRNAs are small transcription regulators of approximately 22 nucleotide in length, targeting more than 50% of the mammalian transcriptome making them unique therapeutic targets [2] . More than 1000 different miRNAs have been identified to exist in humans. They have control over more than half of the mammalian genome and some of their targets are yet to be identified. They constitute silent determinants of cellular metabolism and function. The research to identify their behavior and target regulation has started to gain momentum. In spite of being in focus for only less than a decade, they are known for their increased functional diversity as they play key roles in pathological states. These include development, cell growth, proliferation, differentiation, and cell death [3] [4] [5] [6] [7] . They are also known to play vital roles in chronic immune and inflammatory diseases, genetic diseases, pathogen induced diseases (bacterial and viral), and chronic metabolic diseases, such as diabetes [8] [9] [10] [11] [12] . However, it is still uncertain whether the majority of these miRNAs are the real causes of damages or they represent epiphenomena. The role of miRNAs in diabetes and associated complications started with studies in pancreatic beta cells revealing their potential role in suppression of glucose induced insulin secretion. Thereafter over 500 studies have focused on various miRNAs. Our laboratory has focused on the role of miRNAs in diabetes induced complications [13] [14] [15] . Due to activation of multiple miRNAs following hyperglycemia, focus on a single miRNA as target for treating diabetes or chronic diabetic complications would be challenging. Therefore, Abstract: MicroRNAs (miRNA) are non-coding RNAs, the majority of which are 22 nucleotide in size. They regulate gene transcription and control more than 50% of the mammalian genome. Although functional significance and targets of several miRNAs are yet to be identified, they may be regarded as controller of cellular physiology and function. Through such regulation they play vital roles in normal and diseased states. In the context of diabetes and chronic diabetic complications, recent research has identified alterations of a significant number of miRNAs. However, in a complex chronic disease like diabetes, multiple transcripts may also change in a temporal fashion depending on the disease progression and activation of counter-regulatory mechanisms. Hence, it is also possible that some miRNA changes may not be causally related to the disease pathogenesis and represent epiphenomena. To date, over 500 studies have addressed the role of miRNAs in the pathogenesis of type 1 and type 2 diabetes and chronic diabetic complications. Majority of the altered miRNAs appear to have pathogenetic roles. In this review, we have tried to identify alterations of specific miRNAs and the pathways they may regulate. We have also tried to identify whether some of these miRNA alterations may form basis of potential treatments.
we need to re-evaluate the present scenario and examine whether they have a cause-effect relationship with tissue damage. In this review we have tried to examine the specific pathways and to delineate the information regarding various miRNA alterations in diabetes and associated complications.
How miRNAs act
miRNAs are small transcriptional regulators of approximately 22 nucleotides, belonging to the superfamily of endogenous small RNAs. Using advanced tools in the field of bioinformatics and computational biology like TargetScan, PicTar, EMBL, PITA and miRanda, hundreds of miRNA members have been isolated to date and new ones continue to be discovered. miRNAs are initially transcribed in the nucleus by the RNA polymerase II and then undergo nuclear processing by a close and co-ordinated action of DGCR8 and Drosha proteins [16] . Drosha cleaves the pri-miRNAs to form a stem-loop structure known as pre-miRNA. Drosha recognizes premiRNA as part of a microprocessor complex and makes them vulnerable to be transported out of nucleus with the help of an exporter protein, exportin 5 [17] . Once in the cytosol, they undergo further processing by Dicer, a member of the RNAse III family. Dicer in concert with dsRNA-binding protein, Trbp, cleaves the loops leaving behind a miRNA duplex [18] . One of these strands are involved in the transcriptional regulation forming RNA induced silencing complex (RISC) [19] . For an effective RISC function they require specific proteins called argonaute proteins which together repress translation and ultimately degrade targeted mRNAs [20] . Thus the effect of miRNA mediated target inhibition occurs mostly at the mRNA level through cleavage, decay or translational inhibition depending upon the sequence complementarity.
Role of miRNAs in the pathogenesis of diabetes
There is significant interest with regard to the role of miRNAs in the pathogenesis of diabetes and associated complications. Several studies have identified the role of miRNAs in pancreatic function, with regard to insulin synthesis, secretion and adipose tissue metabolism (contributor towards systemic insulin resistance) [21] [22] [23] [24] [25] . Hence, such processes may potentially contribute to the pathogenesis of both type 1 and type 2 diabetes. With regards to specific miRNAs, miR-9 is a major regulator of pancreatic insulin secretion following glucose exposure by stimulating the activity of secretary granule protein, granuphilin [26] . miR-375 has been shown to regulate glucose homeostasis through α and β cell turnover. Furthermore, it can cause β-cell expansion in response to increasing insulin demand [27] . Secretary efficiency of the pancreas can also be enhanced by miR-7 mediated regulation of its development during embryogenesis [28] . Knockdown studies of miR-7 in mice has shown a decrease in pancreatic differentiation, reduced insulin content and increased beta cell apoptosis [29] . In MIN-6 (mouse insulinoma) and INS-1 (rat insuloma) cells, miR-124a overexpression decreased Kir6.2 and Sur-1 mRNA levels, which are required for K + homeostasis in the beta cells, thus decreasing basal and glucose stimulated insulin secretion [30] . Insulin secretion by the islets is further regulated by counteractive action of miR-15a and miR-33a. They act by suppressing uncoupling protein-2 mRNA and increasing cholesterol accumulation in beta cells through inhibition of cholesterol efflux protein ABCA1 [31, 32] . The insulin production in MIN-6 cells is also influenced by miR-19b through its ability to downregulate NeuroD1, a major transcription factor involved in insulin gene expression [33] .
In rats with type 2 diabetes, miR-144 has been shown to be of pathogenetic significance causing impaired insulin signaling by reducing insulin receptor substrate 1 (IRS-1) [34] . miR-25 and miR-92a suppress insulin gene transcription, insulin synthesis and secretion, an effect normalized by treatment with specific antagomirs in rats [35] . β cell function is affected by maturity onset of diabetic in young (MODY) genes; additionally, other regulators such as HNF1a and NeuroD1 altered by increased levels of miR-24 [36] . In diabetic db/db mice, miR-30d showed a protective effect on pancreatic islets through its ability to augment MafA, a transcription factor that regulates mRNA expression of insulin gene and its receptor substrate [37] . These studies indicate prominent regulatory roles of miRNAs in pancreatic health and homeostasis through regulation of insulin synthesis and secretion. Targeting one or more of these miRNAs may potentially constitute a rational therapeutic approach to correct impaired insulin secretion. Adipose tissue metabolism plays a major role in regulating insulin resistance, a major factor in type 2 diabetes. Interestingly, some prominent studies have shown that miRNAs, by regulating adipose tissue metabolism or their mass, contribute towards insulin resistance. Increased adipogenesis, observed in obesity models of insulin resistance, is inhibited through peroxisome proliferatoractivated receptor γ (PPAR γ) inhibition mediated by increased levels of miR-130a and miR-130b [38, 39] . At the same time expression levels of these miRNAs are reduced in adipocytes isolated from obese individuals, indicating their regulatory roles in adipogenesis and insulin resistance [38] . Adipose tissues from adult humans with low birth weight and pre-diabetic rats showed increased expression of 483-3p. Located on the insulin-like growth factor 2 (IGF2) locus, this miRNA is known to cause dysregulation in adipogenesis and its storage, promoting lipotoxicity and insulin resistance. These effects are mediated through growth/differentiation factor -3, a target of miR-483-3p, and reversed by miR-483-3p inhibition [40] . Lipodysfunction may also occur through inhibition of miR-103 and miR-143 in ob/ob and diet induced obese mice. [41] . Overexpression of these miRNAs normalizes adipocyte differentiation and prevents lipodysfunction. Induction of brown adipose tissue functions may be a potential therapy in obesity and diabetes; they burn calories and are functionally involved in regulation of thermogenesis [42] . Over expression of miR196a in adult human fat cells increases brown fat content thus increasing energy utilization and maintaining the insulin sensitivity of fat cells. It performs these functions through regulation of CEBP/β, a transcription co-factor [43] . It was shown in human adipose tissues and in monocyte/ macrophage cells that miR-126 and miR-193 overexpression attenuates CCL2 (chemokine ligand CCL2) production and secretion, thus decreasing adipocyte inflammation and preventing insulin resistance [44, 45] . Overexpression of miR-93 in adipocytes also leads to downregulation of GLUT4, causing impaired insulin receptor signaling and deterioration of the insulin resistance [46] . Insulin resistant liver cells and cultured hepatocytes, with increased expression of miR-181a, showed a decrease in Sirt1 expression and activity. Such hepatic insulin resistance and dysregulated glucose homeostasis can be reversed by inhibition of miR-181a [47] .
Further focused studies on miRNAs may help in identifying optimum therapeutic target(s) through which insulin resistance may be hindered or slowed down. Identification of a common upstream regulator of all these miRNAs may also be an ideal strategy for regulating insulin resistance.
Role of miRNAs in chronic diabetic complications in various organs
miRNAs possibly play important roles in chronic diabetic complications. These include renal injury, cardiovascular diseases, retinal damage, hepatic inflammation and blood vessel dysfunction. Hyperglycemia is the key initiating event leading to all chronic diabetic complications [48, 49] Hyperglycemia alters cellular metabolism causing oxidative stress and DNA damage. Such alterations derange cellular transcriptional machinery and cause augmented production of effector molecules such as collagen, fibronectin (FN) and vascular endothelial growth factor (VEGF) leading to tissue damage [50, 51] . In the following sections, we will discuss miRNA alterations in specific complications.
Renal Complications
One of the hallmarks of diabetic nephropathy is renal sclerosis associated with impaired function. This is biochemically manifested by increased production of extracellular matrix protein and deposition of collagen, FN and MMP in the kidneys. In streptozotocin-induced diabetic mice and db/db mice, diabetes causes increased TGF-β1 signaling resulting in increased extracellular matrix protein deposition associated with increased expression of miR-192 [52] . miR-192 inhibition attenuated collagen deposition even in the presence of hyperglycemia, establishing a cause-effect relationship. Interestingly, in another study done by Krupa and colleagues, renal biopsies in human diabetic nephropathies and in vitro studies of proximal tubular cells treated with TGF-β1, showed downregulation of miR-192 followed by reduced E-cadherin [53] . Overexpression of miR-192 has shown to have protective effects against TGF-β1 mediated E-cadherin inhibition. This study was supported by Wang B et al who showed that in the tubular and mesanglial cells of diabetic kidneys, miR-192/215 levels were decreased and their overexpression enhanced both E-cadherin levels and fibrogenesis mediated by zinc finger E-box binding homeobox2 (ZEB2), a miR-192/215 target [54] . It has also been revealed that persistent TGF-β1 signaling induces a feedback loop and unregulated activation of miR-192, an effect which was nullified by downregulation miR-192 even in the presence of an activated TGF-β1 signaling [55] . Hence, it is possible that the same miRNA may show different actions regarding TGF-β1 signaling. The duration or severity of diabetes or the presence of a negative feedback loop on active miR-192 could be potential reasons for such changes.
With respect to other miRNAs, Wang et al has shown that miR-377 is upregulated in hyperglycemia and is involved in indirect upregulation of FN protein by inhibition of its upstream inhibitors, superoxide dismutase and p21 activated kinase [56] . miR-21 also has a protective role during diabetes induced kidney diseases as expression of this miRNA drops following diabetes [57, 58] . Under normal conditions collagen production is repressed by miR-29 family (a/b/c). However in hyperglycemic conditions, TGF-β1 signaling inhibits their expression promoting kidney fibrosis [59, 60] . miR-29c is considered one of the bad miRNAs due to its involvement in renal fibrosis by inhibiting sprouty homologue (SPRY1) protein and upregulating the Rho Kinase signaling [61] . Increased miR-29c leads to increased deposition of extracellular matrix in the renal mesanglial cells of diabetic mice. Inhibition of miR-29c attenuates matrix accumulation and albuminuria [62] . Recently, Wang et al demonstrated that miR-let-7b has a protective effect in diabetes-induced renal fibrosis through an inhibitory effect on TGF-β1receptor and its downstream signaling. Therefore miR let-7b is proposed as a therapeutic target for renal fibrosis in diabetic nephropathy [63] . In an interesting study, Long et al have shown that hyperglycemia, by downregulating minichromosome maintenance (MCM7) promoter, reduces miR-93, which normally inhibits VEGF-A expression, along with collagen and FN deposition in podocytes [64] .
Both miR-29a and miR-200b have been shown to influence collagen formation by reducing collagen transcripts and protein deposition. Xiong M et al had shown that miR-200a and miR-200b are down regulated through TGF-β1 signaling [65] . This pathway plays a major role in tubular epithelial cells of kidneys undergoing mesenchymal transformation, a process involved in progression of renal fibrosis. TGF-β1, acting on miR200b, releases its inhibition on ZEB, which normally promote inhibition of E-cadherin [66] . In fact, such a blockade of miR-200a and miR200b mimic the effects of TGF-β1 treatment [67] . Study by Wang B et al also supported this notion and showed that miR-200a along with miR-141 prevented epithelial to mesenchymal transformation in tubular epithelial cells following TGF-β2 stimulation, preventing renal tubular fibrosis [68] . In diabetic nephropathy, it has further been shown that enhanced miR-200b/c expression and Akt stimulation lead to glomerular mesanglial hypertrophy mediated by augmented TGF-β signaling [69] . Disruption of TGF-β1 signaling or downregulation of miR-200b/c resulted in decreased mesanglial hypertrophy. Hence, miR-200b may be mechanistically important for both hyperglycemia induced fibrosis and hypertrophy [69] .
Several miRNAs are known to influence FN synthesis. The list include miR 1207-5b,miR 146a and miR21 [14, 70, 71] . miR-21 has been shown to enhance FN deposition and promote fibrosis in kidneys with the involvement of transducer of regulated CREB activity 1(TORC1) proteins. Downregulation of miR-21 imparts protection against this situation [71] . TGF-β2 receptors target miR-302d, one of the protective miRNA. Increased TGF-β receptor stimulation in conditions like chronic hyperglycemia, leads to enhanced suppression of miR-302d [72] . Conversely, upregulation of miR-302d in mice models confers protection against fibrosis, even in the presence of TGF-β receptor stimulation.
In addition to pathogenetic roles in diabetic nephropathy, some miRNAs, such as miR-10a and miR-30d, are detected in urine, making them potential biomarkers or indicators of organ damage in diabetes [73] . Such a notion, however, needs further investigation.
Cardiovascular Complications
Diabetic cardiomyopathy is mediated through cardiomyocyte and microvascular damage via a complex scenario involving cardiomyocyte hypertrophy, focal fibrosis, calcium and ATP imbalance, increased ROS formation and cell death [74, 75] . We were the first to report a protective role of miR-133a in the cardiac tissue, under hyperglycemia-induced hypertrophic response [13] . In our study, using a two month old STZ induced diabetic mice model, we observed an increase in hypertrophic signaling that accompanied an elevation in mRNA expression of natriuretic peptides ANP, BNP, serum glucocorticoid kinase 1 and IGF1. These were associated with a contractile dysfunction of the ventricular myocardium, an effect also seen in cardiomyocytes exposed to high glucose levels. Transfection of miR-133a mimics in cardiomyocytes under high glucose, nullified the hypertrophic signal [13] . A recent study with miR-133a transgenic mice showed protective effects of miR-133a against hypertrophy as well as fibrosis in diabetes [76] . Expressions of the markers of fibrosis (TGF-β1, CTGF, FN and collagen4A1 mRNA levels) were enhanced in the diabetic hearts. On the other hand, transgenic mice overexpressing miR-133a were able to prevent the diabetes-induced increase in extracellular matrix protein production and cardiac injury associated with fibrosis [77] . These studies indicate that miR-133a is a mediator of diabetes induced cardiac injury. Such a notion is further supported by clinical studies in human subjects. Left ventricular biopsies of patients with ischemic heart disease with types 2 diabetes showed that miR-372, miR34b, miR-199a, miR-199b and miR-485-5p were increased, whereas miR-10a, miR-133a, miR-221 miR-222, and miR-338 were decreased [78] . Additional studies are required to uncover specific roles of these additional miRNAs regulated in diabetic heart disease.
Interestingly, in HL-1 cardiomyocytes exposed to high glucose, and in mice models of diabetes, an increase in DNA methylation is mitigated by miR-133a overexpression [79] . Our group has also shown decreased miR-146a expression accompanied by overexpression of its target protein, FN in cardiac and renal tissues of animals with type 1 and 2 diabetes [14] . A more detailed mechanistic study in endothelial cells revealed p300 mediated histone acetylation caused decreased expression levels of miR-146a in hyperglycemia. Nevertheless, miR-146a mimics were able to prevent increased FN production in endothelial cells even in the presence of high glucose [14] . In the hearts of db/db mice, miR-155 generated diabetesinduced pro-fibrotic myocardial infarction. However, bone marrow-derived progenitor cell therapy augments cardiac performance by its paracrine effects on cardiac cells by inhibiting miR-155 expression levels through hepatocyte growth factor release [80] . Furthermore, neonatal rat cardiomyocytes exposed to high glucose were shown to have decreased miR-373 expression, causing upregulation of MAP kinases, such as ERK and JNK signaling and hypertrophy. Such changes are prevented by miR-373 overexpression [81] . On the other hand, miR -1 and miR-206 were found to be increased in high-glucose exposed cardiomyocytes and promoted apoptosis through Hsp60 proteins [82] .
Vascular endothelium, a protective layer plays a major role in pathogenesis of most, if not all, diabetic complications. In diabetes, there is an alteration or imbalance in the equilibrium of endothelial metabolism and function, which acts as a major initiating event of cardiovascular damage [83, 84] . In cardiac microvascular endothelial cells from rats with type 2 diabetes, an increase in miR-320 was accompanied by decreased expression levels of its target genes IGF-1 and IGF-1R [85] . On the other hand, we have found reduced miR320 in the whole heart in a model of type 1 diabetes [86] .
As mitochondria are the ATP generation houses within a cell, maintaining a mitochondrial balance or health is very important, especially during hyperglycemia induced stress. miR-141 has been shown to regulate mitochondrial inner membrane phosphate transporter mRNA and protein expression. As a result ATP synthase activities were decreased in the hearts of animals with type 1 diabetes [87] . Upregulation of miR-141 may potentially be a strategy to safeguard mitochondrial health and function in diabetes. Diabetic hearts are at a very high risk of sudden deaths primarily attributed to decreased expression of voltage gated potassium channels [88] . At the cellular level, miR-301a is the major upstream regulator of the potassium channel. Increase in expression levels of miR301a in diabetes has an inhibitory effect on the potassium channel expression [89] .
Atherosclerosis is the main factor for cardiovascular risks in diabetes. Experimentally, high fat administered ApoE deficient insulin resistant mice subjected to mechanical vascular stenosis showed increase in atherosclerotic plaque development and this coincided with an increase in expression of miR-322. Using antagomirs for miR-322, inflammatory marker expression in the macrophages was decreased with alleviation of plaque progression [90] .
Hyperglycemia also increased miR-221 expression in cultured endothelial cells, which negatively regulated c-kit. Oligonucleotide mediated inhibition of miR-221 reversed such endothelial dysfunction [91] . Based on these observations, it appears that miRNAs play pathogenetic roles in cardiovascular complications of diabetes.
Retinal Complications
Diabetic retinopathy is one of the major causes of impaired vision or irreversible vision loss.
Multiple biological processes, such as increased angiogenesis, increased permeability, augmented extracellular matrix production and cell death are involved in such process. Studies in our lab have shown that miR-200b has antiangiogenetic and anti-permeability properties due to its regulatory action on VEGF expression. These mechanisms were confirmed using diabetic rat models and in retinal endothelial cells incubated with high glucose [15] . Transfection of endothelial cells with miR-200b mimic and intravitreal administration of miR-200b mimic in diabetic rats alleviated VEGF production and its effects [15] . Furthermore, antagomirs of miR-200b mimicked a hyperglycemic condition with increased permeability and angiogenesis. We have also reported that miR-200b regulates transcription co-activator p300 and some of the miR200b's actions may be mediated through this regulatory role. In the retina of type1 diabetic mice, oxidative stress downregulates oxidation resistance 1 gene (Oxr1), thus increasing cell death. Transfection of human retinal Müller cells with miR-200b mimic further repressed Oxr1 mRNA, decreased oxidative resistance and enhanced cell death [92] . Hence, it is notable that miR200b treatment may have several beneficial effects on diabetic retinopathy.
Kovacs et al showed that miRNAs that target p53, VEGF and NFκβ are differentially regulated in both retina and retina-derived endothelial cells in order to promote angiogenesis. They performed a thorough analysis using in vitro functional assays with an immortalized retinal capillary endothelial cell line showing a marked decrease in miR-146a, a target of NFκβ [93] . Our lab has shown that hyperglycemia promotes the extracellular matrix FN deposition in the retinal tissue in both type 1 and type 2 diabetic animals and in retinal endothelial cells through miR-146a [94] . miR-146a binds to the 3' untranslated region of FN mRNA and negatively regulates its production and expression at the post transcriptional level. A p300 mediated miR-146a downregulation led to increased FN production and such changes were preventable both in vivo and in vitro using miR146a mimic [14] . It has also been shown that miR146a expression may vary temporally, as it gets upregulated at the later stages of diabetic retinopathy [14] . Silva et al showed that miR-29b regulates activation of pro-apoptotic RNA-dependent protein kinase (PKR) associated protein X (RAX) in the retinas of diabetic rats [95] . This correlation gives us an indication to explore deeper and understand better the protective role of miR-29b as a therapeutic target in diabetes induced retinal cell death. In a recent miRNA profiling, miR-183, miR-211, miR-204, miR-182, miR-96 and miR-124 were significantly increased following the progression of diabetes retinopathy and miR-10b, miR-10a, miR-219-2-3p, miR-144, miR-338 and miR199a-3p levels were reduced [96] . Further specific studies however are needed to understand biologic roles of these miRNAs. Recently, miR106a has been demonstrated to regulate both hypoxia inducible factor 1 α (HIF 1α) and VEGF indicating a possible pathogenetic role in diabetic retinopathy [97] . A study by Kovacs et al has shown that in STZ-induced diabetic rats, miR-21 and miR-132 are upregulated and control a NF-κB responsive target gene promoting diabetic retinal diseases. An inverse effect is observed in the expression levels of miR-181 in these mice [93] . Recovery or overexpression studies are warranted to validate if there is any protective action offered by miR-181 in diabetes.
Hepatic Complications
Early metabolic changes that occur in the liver may be the major cause of insulin resistance and thus type 2 diabetes. On the other hand, an aggravated insulin resistant state or progression of type 2 diabetes may result in hepatic inflammation and steatosis, namely nonalcoholic steato-hepatitis (NASH). Diabetes induced lipotoxicity is considered to be a major etiologic factor for this condition [98] . It has been shown that upregulation of miR-103 and miR-107 lead to insulin resistance, and silencing of these miRNAs in hepatocytes and normalized insulin sensitivity in adipocytes [99] . Parallel studies by other groups have shown an increase in miR-103 and miR-95 expression in the livers of diabetic rats [100] . An early study by Li et al in both type 1 and type 2 diabetic mice, described a upregulation of miR-34 while miR-122 was down regulated, indicating potential roles in the regulation of glucose metabolism [101] . Such analysis raises the possibility whether regulating these miRNAs, may lead to regulation of the liver inflammatory diseases in diabetes? However, the role of specific miRNAs in this context remains to be explored. Another study of miRNAs in type 2 diabetes has shown that miR-125a, with multiple target proteins in glucose and lipid metabolism, shows high levels of upregulation in the liver [102] . miR-155 has also been shown to be of importance in the liver of type 2 diabetes as miR-155 knockout mice show features of NASH [103] . In human hepatocytes (huh-7 cells), miR-181d causes a decrease in hepatic lipid droplet content, cellular triglyceride content and cholesterol esters [104] . Recently, increased miR-143 and miR-145 in liver tissues of obese mice have shown to cause impaired insulin signaling and aggravated insulin resistance through downregulation of oxysterolbinding-protein-related protein 8 [105] . Interestingly, in Zucker diabetic fatty rats, miR-29b regulates survival signaling and promotes lipotoxicity. Inhibition of miR-29b increases protective signaling, including AKT and AMPK, normalizing lipotoxic dysfunction [106] . Thus, exploring the miRNAs of pathogenetic significance in the liver may identify new treatment targets.
miRNAs in circulation in diabetes
Apart from their role in regulating pathogenesis and complications associated with diabetes, miRNAs may also act as potential biomarkers of tissue damage in diabetic complications. We have already mentioned presence of specific miRNAs in the urine. Studies using plasma miRNA profiling of type 2 diabetic patients showed decreased levels of miR-15a, miR-20b, miR-21, miR-24, miR-223, miR-320, miR-126, miR-191, miR-197, and miR-486. However, the expression level of miR-28-3p was increased [107] . In type 2 diabetic individuals, increased plasma miR-503 and miR-126 expression were found to correlate with angiogenesis [108, 109] . Blood samples from type 2 diabetes patients and rat models, showed increased miR-144, correlating with insulin receptor substrate 1(IRS-1) level and decreased insulin sensitivity [110] . In addition, serum studies in diabetes have shown increased miR23a, miR- 16-2, miR-15b, miR-106b, and miR-195a, whereas miR-17, miR-18a, miR-20a, miR-24-2, miR-27a, miR-365, miR-193b, miR-224, miR-452, miR-107 and miR103 were decreased [111] . Some of these miRNAs are not only expressed in plasma but also in specific tissues making them potential biomarkers. It is further to be noted that tissue expression of various miRNAs may not always co-relate with serum levels [112] . This is possibly due to their biogenesis and mechanisms of action. However, additional studies are needed to establish their specific roles for such applications.
Concluding remarks
One of the main challenges in studying the role of miRNAs in diabetes, and associated complications, is due to the complexity of a chronic disease and organ specific alterations. A miRNA which is beneficial in one organ may not have a similar effect on other tissues. Furthermore, their differential expression patterns stirs the doubt whether they are the real perpetrators that cause the damage or gets turned on following diabetes as epiphenomena. As is evident from the above discussion, several miRNAs have been shown to be altered in diabetes and chronic diabetic complications. A significant volume of cellculture and preclinical studies has shown that specific miRNAs are causally related to specific tissue damage and have pathogenetic role in specific complications. Table -1 summarizes various miRNA changes in diabetes and in specific chronic diabetic complication. Hence, miRNAs offer unique opportunities for development as treatment targets and biomarkers. Compared to protein and small molecule, RNA based therapeutics offer unique advantages, such as specificity. However, as one miRNA may target multiple transcripts and a single transcript can be targeted by multiple miRNAs, miRNA based treatment presents with unique potential and challenges. There are several miRNA based therapies under development for various disease processes, and many of these are [113] .
With the rising levels of diabetes worldwide, focus must be turned towards miRNAs that could regulate either the pathogenesis of diabetes and/or chronic diabetic complications. Type 1 and Type 2 manifest different pathogenic pathways but ultimately culminate in similar complications of the target organs. It is debatable whether normalizing their pattern of expression rather than targeting specific miRNAs should be the guiding compass. miRNAs like miR-7, and miR-9, have shown to be protective in the pancreas and involved with insulin synthesis and secretion in a positive manner [114, 115] . miRNAs such as miR-15b and miR-144 have been shown to have a debilitating effect on both pancreatic function and insulin synthesis [34, 116] . Direct manipulation of miRNAs has been shown to have specific effects in some chronic complications [14, 15, 86] . It would be interesting to see whether one beneficial miRNA can turn on a cascade of other beneficial/ or detrimental miRNAs and/ or other epigenetic events. However, with their diverse roles in development, metabolism, maintaining structural integrity, function and cell survival, it would be tough to coin one as a "good" or "bad" miRNA. Thus a detailed study exploring the role of individual miRNA in diabetes in a tissue specific manner would reveal their actual role in diabetes (Figure 1 ) and would help us in developing therapeutic targets based on miRNA.
